Haleon plc (HLN)
| Market Cap | 41.88B |
| Revenue (ttm) | 15.10B |
| Net Income (ttm) | 2.09B |
| Shares Out | 9.03B |
| EPS (ttm) | 0.23 |
| PE Ratio | 40.68 |
| Forward PE | 18.23 |
| Dividend | $0.18 (1.95%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 6,240,829 |
| Open | 9.25 |
| Previous Close | 9.38 |
| Day's Range | 9.25 - 9.36 |
| 52-Week Range | 8.71 - 11.42 |
| Beta | 0.23 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Jul 31, 2025 |
About HLN
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprisi... [Read more]
Financial Performance
In 2024, Haleon's revenue was 11.23 billion, a decrease of -0.61% compared to the previous year's 11.30 billion. Earnings were 1.44 billion, an increase of 37.46%.
Financial numbers in GBP Financial StatementsNews
Haleon plc (HLN) Q3 2025 Sales Call Transcript
Haleon plc ( HLN) Q3 2025 Sales Call October 30, 2025 5:00 AM EDT Company Participants Joanne Russell - Head of Investor Relations Dawn Allen - CFO & Director Conference Call Participants Guillaume G...
UK's Haleon posts third-quarter organic revenue marginally above estimates
British consumer healthcare group Haleon reported third-quarter organic revenue growth marginally above market estimates on Thursday, helped by strong demand for its oral health products.
Harding Loevner International Equity ADR Q3 2025 Portfolio Update
The International Equity ADR composite rose 3.0% gross of fees in the second quarter, behind the 7.0% gain of the MSCI ACWI ex US Index. In Communication Services, Tencent delivered a second consecuti...
FTSE 100 Index shares to watch: HSBC, Standard Chartered, Haleon, GSK
The FTSE 100 Index rose for four consecutive days and reached its all-time high of £9,578 as traders reacted to key earnings and macro data. It has jumped by over 27% from its lowest level this year.
Haleon Selects Salesforce Agentforce Life Sciences Cloud for Customer Engagement to Improve Engagement with Pharmacies and Healthcare Professionals with AI
LONDON & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Haleon plc (LSE/NYSE:HLN), a leading global consumer company that specialises in everyday health and Salesforce (NYSE:CRM), the world's #1 AI CRM, today ...
School's in and immune systems are up, with new Emergen-C Junior Crystals for kids
Help keep your kids smiling and sniffle-free this back-to-school season with a tasty new “popping” boost of immune-supporting vitamins and minerals. Help keep your kids smiling and sniffle-free this b...
Haleon Plc (HLN) Presents At Barclays 18th Annual Global Consumer Staples Conference 2025 Transcript
Haleon plc (NYSE:HLN) Barclays 18th Annual Global Consumer Staples Conference 2025 September 2, 2025 11:15 AM EDT Company Participants Brian McNamara - CEO & Executive Director Conference Call Partic...
Haleon plc (HLN) Q2 2025 Q&A Earnings Call Transcript
Haleon plc (NYSE:HLN) Q2 2025 Earnings Q&A Conference July 31, 2025 4:30 AM ET Company Participants Brian James McNamara - CEO & Executive Director Dawn Amanda Allen - CFO & Director Jo Russell - Hea...
Haleon CEO: 'Quite optimistic about emerging market growth'
Brian McNamara, chief executive of of Haleon said the company is "quite optimistic about emerging market growth," whilst still developing a "great" business in developed markets.
UK's Haleon cuts annual organic revenue growth forecast
British consumer healthcare company Haleon lowered its annual organic revenue growth forecast to 3.5% on Thursday, citing weaker performance in the United States.
Haleon Breaks Ground on new £130m Global Oral Health Innovation Centre
LONDON--(BUSINESS WIRE)-- #Groundbreaking--This week, Haleon, a global leader in consumer health and maker of leading brands such as Sensodyne, parodontax and Polident, broke ground on its new Global ...
HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER
LONDON , June 24, 2025 /PRNewswire/ -- Haleon (LSE: HLN) (NYSE: HLN) today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025.
Whitening without the pain: Sensodyne Clinical White gives Canadians a reason to smile
Sensodyne launches new premium Clinical White toothpaste to brighten Canadians' smiles in time for National Smile Day. Sensodyne launches new premium Clinical White toothpaste to brighten Canadians' s...
Haleon plc (HLN) Q1 2025 Earnings Call Transcript
Haleon plc (NYSE:HLN) Q1 2025 Results Conference Call April 30, 2025 3:30 PM ET Company Participants Jo Russell - Head-Investor Relations Dawn Allen - Chief Financial Officer Conference Call Particip...
Brightseed and Haleon Announce Strategic Collaboration to Harness AI for Small Molecule Discovery and Human Health Innovation
LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Brightseed and Haleon and Announce Strategic Collaboration to Harness AI for Small Molecule Discovery and Human Health Innovation.
Consumer healthcare group Haleon raises medium-term profit forecast
Haleon on Thursday raised its medium-term target for profit growth from 2026, banking on strength in key markets and costs cuts within its supply chain, which would save the consumer healthcare group ...
Haleon reports lower first-quarter revenue hurt by a weaker flu season
British consumer healthcare group Haleon on Wednesday reported a 2.3% fall in its first-quarter revenue as sluggish demand for its cold and cough medicines outside of North America continued to weigh.
UK's Haleon takes full control of Chinese consumer healthcare venture
British consumer healthcare group Haleon said on Tuesday it has gained complete ownership of its Chinese joint venture after acquiring Tianjin Pharmaceutical Da Ren Tang's 12% stake for about 1.62 bil...
Haleon: A Defensive Play That Makes Sense Amidst The Stock Market Sell-Off
As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding margin...
Pfizer sells entire Haleon stake for $3.24 billion
Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for t...
Pfizer to dispose of entire Haleon stake
Haleon shareholder Pfizer will dispose of its entire 7.3% stake in the British consumer healthcare group, a bookrunner said on Tuesday.
2 Attractively Priced, High Yield Stocks For Income Durability As The Market Hits New Highs
Hyperinflation and high interest rates make dividend-paying stocks attractive, providing cash flow and alleviating inflation pressure. Pfizer's 6% yield is appealing despite recent stock declines, wit...
Haleon: Growing Profits And Dividend
I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered by fr...
Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025
London-based consumer healthcare group Haleon Plc HLN stock is trading lower on Thursday.
Haleon CEO: We're relatively low-exposed to tariffs
Haleon CEO Brian McNamara says his company is not as exposed as peers to tariff risks, as the consumer healthcare company reports full-year results